News Home

What is the Market's View on Vertex Pharmaceuticals Incorporated (VRTX) Stock's Price and Volume Trends Friday?

Friday, December 01, 2023 03:38 PM | InvestorsObserver Analysts

Mentioned in this article

What is the Market's View on Vertex Pharmaceuticals Incorporated (VRTX) Stock's Price and Volume Trends Friday?

Vertex Pharmaceuticals Incorporated (VRTX) stock is lower by 0.63% over the past week and gets a Bullish rating from InvestorsObserver Sentiment Indicator.

Sentiment Score - ,bullish
Vertex Pharmaceuticals Incorporated has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on VRTX!

What is Stock Sentiment?

In investing, sentiment generally means whether or not a given security is in favor with investors. It is typically a pretty short-term metric that relies entirely on technical analysis. That means it doesn’t incorporate anything to do with the health or profitability of the underlying company. Sentiment is how investors, or the market, feels about a stock. There are lots of ways to measure sentiment. At the core, sentiment is pretty easy to understand. If a stock is going up, investors must be bullish, while if it is going down, sentiment is bearish. InvestorsObserver’s Sentiment Indicator looks at price trends over the past week and also considers changes in volume. Increasing volume can mean a trend is getting stronger, while decreasing volume can mean a trend is nearing a conclusion. For stocks that have options, our system also considers the balance between calls, which are often bets that the price will go up, and puts, which are frequently bets that the price will fall.

What's Happening With VRTX Stock Today?

Vertex Pharmaceuticals Incorporated (VRTX) stock is down -1.12% while the S&P 500 is up 0.57% as of 3:31 PM on Friday, Dec 1. VRTX is lower by -$3.99 from the previous closing price of $354.81 on volume of 668,347 shares. Over the past year the S&P 500 has gained 12.59% while VRTX is up 10.88%. VRTX earned $13.32 a per share in the over the last 12 months, giving it a price-to-earnings ratio of 26.34. To screen for more stocks like Vertex Pharmaceuticals Incorporated click here.

More About Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes. Click Here to get the full Stock Report for Vertex Pharmaceuticals Incorporated stock.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App Android App